Children and young people are far less likely than adults to get severe cases of Covid-19 infection, and death from the pandemic disease among children is exceptionally rare, according to published UK research.

A look at U.S. Food and Drug Administration PDUFA dates for end-of-August and early-September 2020.

Novavax Inc. began enrolling volunteers for the second phase of an ongoing clinical trial of the company’s Covid-19 vaccine candidate, with interim data expected in the fourth quarter of 2020.

The U.S. Food and Drug Administration approved Novartis’ Kesimpta (ofatumumab, formerly OMB157) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis in adults.

A phase IIIb study in the United States that evaluated Dovato (dolutegravir/lamivudine) for rapid initiation of treatment after diagnosis in adults with HIV-1 found the medicine to be effective and well tolerated in the setting, indicating the feasibility of its use in Test and Treat strategies.

The U.S. Food and Drug Administration approved Roche’s Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion’s Soliris in a costly treatment area.

The U.S. Food and Drug Administration approved MorphoSys and Incyte’s Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

Boehringer Ingelheim and Eli Lilly announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.

Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

The U.S. Food and Drug Administration approved GlaxoSmithKline Plc’s HIV drug Rukobia to treat adult patients who have run out of treatment options.